Exploring the effect of vitamin D<sub>3</sub> supplementation on the anti-EBV antibody response in relapsing-remitting multiple sclerosis
| LEADER | naa a22 4500 | ||
|---|---|---|---|
| 001 | 528959670 | ||
| 003 | CHVBK | ||
| 005 | 20180926082331.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 180926e201809 xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1177/1352458517722646 |2 doi |
| 035 | |a (SERVAL)BIB_FD2BEB7A97DB | ||
| 091 | |a 28731372 |b pmid | ||
| 091 | |a 000442395000006 |b isiid | ||
| 245 | 0 | 0 | |a Exploring the effect of vitamin D3 supplementation on the anti-EBV antibody response in relapsing-remitting multiple sclerosis |h [Elektronische Daten] |c [L. Rolf, A.H. Muris, A. Mathias, R. Du Pasquier, I. Koneczny, G. Disanto, J. Kuhle, S. Ramagopalan, J. Damoiseaux, J. Smolders, R. Hupperts] |
| 520 | 3 | |a Epstein-Barr virus (EBV) infection and vitamin D insufficiency are potentially interacting risk factors for multiple sclerosis (MS). To investigate the effect of high-dose vitamin D <sub>3</sub> supplements on antibody levels against the EBV nuclear antigen-1 (EBNA-1) in patients with relapsing-remitting multiple sclerosis (RRMS) and to explore any underlying mechanism affecting anti-EBNA-1 antibody levels. This study utilized blood samples from a randomized controlled trial in RRMS patients receiving either vitamin D <sub>3</sub> (14,000 IU/day; n = 30) or placebo ( n = 23) over 48 weeks. Circulating levels of 25-hydroxyvitamin-D, and anti-EBNA-1, anti-EBV viral capsid antigen (VCA), and anti-cytomegalovirus (CMV) antibodies were measured. EBV load in leukocytes, EBV-specific cytotoxic T-cell responses, and anti-EBNA-1 antibody production in vitro were also explored. The median antibody levels against EBNA-1, but not VCA and CMV, significantly reduced in the vitamin D <sub>3</sub> group (526 (368-1683) to 455 (380-1148) U/mL) compared to the placebo group (432 (351-1280) to 429 (297-1290) U/mL; p = 0.023). EBV load and cytotoxic T-cell responses were unaffected. Anti-EBNA-1 antibody levels remained below detection limits in B-cell cultures. High-dose vitamin D <sub>3</sub> supplementation selectively reduces anti-EBNA-1 antibody levels in RRMS patients. Our exploratory studies do not implicate a promoted immune response against EBV as the underlying mechanism. | |
| 700 | 1 | |a Rolf |D L. |4 aut | |
| 700 | 1 | |a Muris |D A.H. |4 aut | |
| 700 | 1 | |a Mathias |D A. |4 aut | |
| 700 | 1 | |a Du Pasquier |D R. |4 aut | |
| 700 | 1 | |a Koneczny |D I. |4 aut | |
| 700 | 1 | |a Disanto |D G. |4 aut | |
| 700 | 1 | |a Kuhle |D J. |4 aut | |
| 700 | 1 | |a Ramagopalan |D S. |4 aut | |
| 700 | 1 | |a Damoiseaux |D J. |4 aut | |
| 700 | 1 | |a Smolders |D J. |4 aut | |
| 700 | 1 | |a Hupperts |D R. |4 aut | |
| 773 | 0 | |t Multiple sclerosis |g 24/10(2018-09), 1280-1287 |q 24:10<1280-1287 |1 2018 |2 24 | |
| 908 | |D 1 |a article |2 serval | ||
| 950 | |B SERVAL |P 700 |E 1- |a Rolf |D L. |4 aut | ||
| 950 | |B SERVAL |P 700 |E 1- |a Muris |D A.H. |4 aut | ||
| 950 | |B SERVAL |P 700 |E 1- |a Mathias |D A. |4 aut | ||
| 950 | |B SERVAL |P 700 |E 1- |a Du Pasquier |D R. |4 aut | ||
| 950 | |B SERVAL |P 700 |E 1- |a Koneczny |D I. |4 aut | ||
| 950 | |B SERVAL |P 700 |E 1- |a Disanto |D G. |4 aut | ||
| 950 | |B SERVAL |P 700 |E 1- |a Kuhle |D J. |4 aut | ||
| 950 | |B SERVAL |P 700 |E 1- |a Ramagopalan |D S. |4 aut | ||
| 950 | |B SERVAL |P 700 |E 1- |a Damoiseaux |D J. |4 aut | ||
| 950 | |B SERVAL |P 700 |E 1- |a Smolders |D J. |4 aut | ||
| 950 | |B SERVAL |P 700 |E 1- |a Hupperts |D R. |4 aut | ||
| 950 | |B SERVAL |P 773 |E 0- |t Multiple sclerosis |g 24/10(2018-09), 1280-1287 |q 24:10<1280-1287 |1 2018 |2 24 | ||
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 949 | |B SERVAL |F SERVAL |b SERVAL |j article | ||